高血圧症治療薬の市場規模、シェア、動向分析レポート：薬剤クラス別、タイプ別、投与経路別、流通チャネル別、地域別、セグメント別予測、2024年～2030年

高血圧症治療薬市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の高血圧症治療薬市場規模は2030年までに306億9,000万米ドルに達し、2024年から2030年までのCAGRは3.91%で拡大すると予測されています。

高血圧患者の増加が市場成長を促進する主な要因です。また、肥満、がん、心臓病などの慢性疾患の増加や、創薬・個別化医療の革新が高血圧症治療薬市場の成長を促進しています。

良好な結果を示すパイプラインの強力な製品の存在は、高血圧症治療薬市場の需要を促進する主な要因です。例えば、2023年9月、Alnylam Pharmaceuticals, Inc.は、高血圧治療薬ジレベシランの第2相試験が主要評価項目を達成し、収縮期血圧（24時間平均値）の有意な低下を示したと発表しました。ジレベシランは、アンジオテンシノーゲンを標的とするRNAi治療薬で、皮下投与され、アンメットニーズの高い集団を対象とすることが期待されています。

高血圧は糖尿病の一般的な合併症であるため、糖尿病の有病率の増加が高血圧症治療薬市場の成長に拍車をかけています。高血圧は糖尿病の一般的な合併症であり、長期にわたると心臓、血管、腎臓、その他の臓器にダメージを与える可能性があります。糖尿病の有病率が高まるにつれ、高血圧症治療薬の需要も増加すると予想されます。IDF糖尿病アトラス第10版2021によると、20～79歳の成人の糖尿病患者数は推定5億3,700万人で、2030年には6億4,300万人に達すると予想されています。

研究開発活動や流通に対する政府の資金援助は、高血圧症治療薬をより手頃な価格にし、アクセスを改善し、競争を激化させることで、市場の成長を後押しする役割を果たしています。例えば、2023年8月、Eazymed Technologies Pvt Ltd.はインドのTamil Nadu Emerging Sector Seed Fundから50万米ドルを調達しました。同社はこの資金を、製薬会社と直接取引して第2～3級都市でのプレゼンスを拡大するなど、サプライチェーンにおける新規事業に活用する予定です。こうした取り組みが高血圧症治療薬市場の成長を後押ししています。

さらに、新規高血圧症治療薬の承認が増加することで、製薬会社は新規で効果的な治療法の研究開発に投資するようになり、主要プレーヤーに有利な機会を提供することが期待されています。例えば、2022年5月、FDAはTyvaso DPI（トレプロスチニル）吸入粉末を承認しました。Tyvaso DPIは、血管拡張剤であるトレプロスチニルを肺に直接送達するドライパウダー吸入器です。トレプロスチニルは肺動脈を拡張することにより作用し、肺の血圧を下げ、運動能力を向上させる。

高血圧症治療薬市場レポート・ハイライト

• 薬剤クラス別では、カルシウム拮抗薬が、他の高血圧症治療薬との併用における本来の特性により、2023年の市場を独占しました。
• タイプ別では、食事、運動不足、肥満、喫煙、過度の飲酒などのライフスタイルの変化や老年人口の増加により、一次性高血圧治療薬が2023年の市場で最大のシェアを占めました。
• 投与経路別では、経口剤がその利便性、有効性、患者中心のアプローチにより最大のシェアを占めています。
• 流通チャネル別では、幅広いヘルスケアサービスを提供する病院の世界の増加により、病院薬局が市場を独占しています。
• 北米は、民間企業による投資の増加、有利な政府・保険政策、技術の進歩、主要な地域事業者により、37.55%の市場シェアを占め、強い地域地位を確立しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 市場変数、動向、および範囲

• 市場セグメンテーションと範囲
• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
• 市場促進要因
  • 高血圧および高血圧の有病率の増加
  • 高齢者人口の増加
  • 新しくてより効果的な抗高血圧薬の開発
• 市場抑制要因分析
  • 高血圧症治療薬の副作用
  • 規制上の課題
• 事業環境分析
  • SWOT分析;要因別（政治・法律、経済・技術）
  • ポーターのファイブフォース分析

第4章 薬剤クラスのビジネス分析

• 高血圧症治療薬市場：薬剤クラスの変動分析
• 利尿薬
• ACE阻害剤
• カルシウムチャネルブロッカー
• ベータアドレナリン遮断薬
• 血管拡張薬
• その他

第5章 タイプのビジネス分析

• 高血圧症治療薬市場：タイプの変動分析
• 原発性高血圧症
• 二次性高血圧症

第6章 投与経路のビジネス分析

• 高血圧症治療薬市場：投与経路の変動分析
• 経口
• 注射剤
• その他

第7章 流通チャネルのビジネス分析

• 高血圧症治療薬市場：流通チャネルの変動分析
• 小売薬局
• 病院薬局
• オンライン薬局

第8章 地域のビジネス分析

• 地域別高血圧症治療薬市場シェア、2023年および2030年
• 北米
  • 北米の高血圧症治療薬市場推計・予測、2018年から2030年
  • 米国
  • カナダ
• 欧州
  • 欧州の高血圧症治療薬市場推計・予測、2018年から2030年
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋地域
  • アジア太平洋地域の高血圧症治療薬市場推計・予測、2018年から2030年
  • 日本
  • 中国
  • インド
  • 韓国
  • オーストラリア
  • タイ
• ラテンアメリカ
  • ラテンアメリカの高血圧症治療薬市場推計・予測、2018年から2030年
  • ブラジル
  • メキシコ
  • アルゼンチン
• 中東・アフリカ
  • MEA高血圧症治療薬市場推計・予測、2018～2030年
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第9章 競合情勢

• 参入企業の概要
• 財務実績
• 参入企業
  • マーケットリーダー
  • 高血圧症治療薬市場シェア分析、2023年
  • 企業プロファイル
  • 戦略マッピング

List of Tables

• Table 1 List of Abbreviations
• Table 2 Global Anti-hypertensive Drugs Market, by Region, 2018 - 2030 (USD Million)
• Table 3 Global Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 4 Global Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
• Table 5 Global Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 6 Global Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 7 North America Anti-hypertensive Drugs Market, by Country, 2018 - 2030 (USD Million)
• Table 8 North America Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 9 North America Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
• Table 10 North America Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 11 North America Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 12 U.S. Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 13 U.S. Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
• Table 14 U.S. Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 15 U.S. Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 16 Canada Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 17 Canada Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
• Table 18 Canada Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 19 Canada Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 20 Europe Anti-hypertensive Drugs Market, by Country, 2018 - 2030 (USD Million)
• Table 21 Europe Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 22 Europe Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
• Table 23 Europe Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 24 Europe Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 25 Germany Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 26 Germany Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
• Table 27 Germany Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 28 Germany Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 29 UK Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 30 UK Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
• Table 31 UK Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 32 UK Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 33 France Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 34 France Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
• Table 35 France Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 36 France Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 37 Italy Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 38 Italy Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
• Table 39 Italy Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 40 Italy Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 41 Spain Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 42 Spain Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
• Table 43 Spain Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 44 Spain Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 45 Denmark Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 46 Denmark Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
• Table 47 Denmark Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 48 Denmark Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 49 Sweden Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 50 Sweden Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
• Table 51 Sweden Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 52 Sweden Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 53 Norway Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 54 Norway Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
• Table 55 Norway Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 56 Norway Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 57 Asia Pacific Anti-hypertensive Drugs Market, by Country, 2018 - 2030 (USD Million)
• Table 58 Asia Pacific Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 59 Asia Pacific Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
• Table 60 Asia Pacific Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 61 Asia Pacific Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 62 China Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 63 China Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
• Table 64 China Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 65 China Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 66 Japan Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 67 Japan Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
• Table 68 Japan Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 69 Japan Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 70 India Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 71 India Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
• Table 72 India Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 73 India Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 74 South Korea Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 75 South Korea Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
• Table 76 South Korea Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 77 South Korea Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 78 Australia Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 79 Australia Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
• Table 80 Australia Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 81 Australia Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 82 Thailand Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 83 Thailand Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
• Table 84 Thailand Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 85 Thailand Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 86 Latin America Anti-hypertensive Drugs Market, by Country, 2018 - 2030 (USD Million)
• Table 87 Latin America Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 88 Latin America Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
• Table 89 Latin America Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 90 Latin America Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 91 Brazil Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 92 Brazil Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
• Table 93 Brazil Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 94 Brazil Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 95 Mexico Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 96 Mexico Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
• Table 97 Mexico Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 98 Mexico Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 99 Argentina Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 100 Argentina Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
• Table 101 Argentina Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 102 Argentina Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 103 Middle East & Africa Anti-hypertensive Drugs Market, by Country, 2018 - 2030 (USD Million)
• Table 104 Middle East & Africa Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
• Table 105 Middle East & Africa Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 106 Middle East & Africa Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 107 Middle East & Africa Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 108 South Africa Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 109 South Africa Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
• Table 110 South Africa Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 111 South Africa Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 112 Saudi Arabia Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 113 Saudi Arabia Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
• Table 114 Saudi Arabia Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 115 Saudi Arabia Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 116 UAE Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 117 UAE Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
• Table 118 UAE Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 119 UAE Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million)
• Table 120 Kuwait Anti-hypertensive Drugs Market, by Drug Class, 2018 - 2030 (USD Million)
• Table 121 Kuwait Anti-hypertensive Drugs Market, by Type, 2018 - 2030 (USD Million)
• Table 122 Kuwait Anti-hypertensive Drugs Market, by Route of Administration, 2018 - 2030 (USD Million)
• Table 123 Kuwait Anti-hypertensive Drugs Market, by Distribution Channel, 2018 - 2030 (USD Million) 

List of Figures

• Fig. 1 Market research process
• Fig. 2 Information Procurement
• Fig. 3 Primary Research Pattern
• Fig. 4 Market Research Approaches
• Fig. 5 Value Chain-Based Sizing & Forecasting
• Fig. 6 Market Formulation & Validation
• Fig. 7 Anti-hypertensive Drugs Market Segmentation
• Fig. 8 Market Snapshot, 2023
• Fig. 9 Market Trends & Outlook
• Fig. 10 Market Driver Relevance Analysis (Current & Future Impact)
• Fig. 11 Market Restraint Relevance Analysis (Current & Future Impact)
• Fig. 12 PESTEL Analysis, By Factor (Political & Legal, Economic and Technological)
• Fig. 13 Porter's Five Forces Analysis
• Fig. 14 Global Anti-hypertensive Drugs Market: Drug Class Movement Analysis
• Fig. 15 Global Anti-hypertensive Drugs Market, by Diuretics, 2018 - 2030 (USD Million)
• Fig. 16 Global Anti-hypertensive Drugs Market, by ACE Inhibitors, 2018 - 2030 (USD Million)
• Fig. 17 Global Anti-hypertensive Drugs Market, by Calcium Channel Blockers, 2018 - 2030 (USD Million)
• Fig. 18 Global Anti-hypertensive Drugs Market, by Beta-adrenergic Blockers, 2018 - 2030 (USD Million)
• Fig. 19 Global Anti-hypertensive Drugs Market, by Vasodilators, 2018 - 2030 (USD Million)
• Fig. 20 Global Anti-hypertensive Drugs Market, by Others, 2018 - 2030 (USD Million)
• Fig. 21 Global Anti-hypertensive Drugs Market: Type Movement Analysis
• Fig. 22 Global Anti-hypertensive Drugs Market, by Primary Hypertension, 2018 - 2030 (USD Million)
• Fig. 23 Global Anti-hypertensive Drugs Market, by Secondary Hypertension, 2018 - 2030 (USD Million)
• Fig. 24 Global Anti-hypertensive Drugs Market: Route of Administration Movement Analysis
• Fig. 25 Global Anti-hypertensive Drugs Market, by Oral, 2018 - 2030 (USD Million)
• Fig. 26 Global Anti-hypertensive Drugs Market, by Injectables, 2018 - 2030 (USD Million)
• Fig. 27 Global Anti-hypertensive Drugs Market, by Others, 2018 - 2030 (USD Million)
• Fig. 28 Global Anti-hypertensive Drugs Market: Distribution Channel Movement Analysis
• Fig. 29 Global Anti-hypertensive Drugs Market, by Retail Pharmacy, 2018 - 2030 (USD Million)
• Fig. 30 Global Anti-hypertensive Drugs Market, by Hospital Pharmacy, 2018 - 2030 (USD Million)
• Fig. 31 Global Anti-hypertensive Drugs Market, by Online Pharmacy, 2018 - 2030 (USD Million)
• Fig. 32 Regional Marketplace: Key Takeaways
• Fig. 33 Regional Outlook, 2023 & 2030
• Fig. 34 Global Anti-hypertensive Drugs Market: Region Movement Analysis
• Fig. 35 North America Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
• Fig. 36 U.S. Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
• Fig. 37 Canada Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
• Fig. 38 Europe Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
• Fig. 39 Germany Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
• Fig. 40 UK Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
• Fig. 41 France Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
• Fig. 42 Italy Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
• Fig. 43 Spain Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
• Fig. 44 Denmark Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
• Fig. 45 Sweden Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
• Fig. 46 Norway Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
• Fig. 47 Asia Pacific Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
• Fig. 48 Japan Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
• Fig. 49 China Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
• Fig. 50 India Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
• Fig. 51 Australia Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
• Fig. 52 South Korea Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
• Fig. 53 Thailand Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
• Fig. 54 Latin America Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
• Fig. 55 Brazil Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
• Fig. 56 Mexico Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
• Fig. 57 Argentina Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
• Fig. 58 Middle East and Africa Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
• Fig. 59 South Africa Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
• Fig. 60 Saudi Arabia Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
• Fig. 61 UAE Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)
• Fig. 62 Kuwait Anti-hypertensive Drugs Market, 2018 - 2030 (USD Million)

Anti-hypertensive Drugs Market Growth & Trends:

The global anti-hypertensive drugs market size is expected to reach USD 30.69 billion by 2030, expandingat a CAGR of 3.91% from 2024 to 2030, according to a new report by Grand View Research, Inc. Rising patient base of high blood pressure is the primary factor propelling market growth. Moreover, increasing cases of chronic diseases such as obesity, cancer, and heart disease and innovations in drug discovery & personalized medicine are increasing the growth of anti-hypertensive drugs market.

Presence of strong product in the pipeline demonstrating positive results is a major factor driving the demand for anti-hypertensive drugs market. For instance, in September 2023, Alnylam Pharmaceuticals, Inc. announced the phase 2 study on an investigation drug for the treatment of hypertension, zilebesiran, met the primary end-point and demonstrated significant reduction in the systolic BP (24 hour mean). Zilebesiran is an RNAi therapeutic targeting angiotensinogen which is administered subcutaneously and is expected to target high unmet need in populations.

The growing prevalence of diabetes is fueling the anti-hypertensive drugs market growth, as hypertension is a common complication of diabetes. Over time, hypertension can damage the heart, blood vessels, kidneys, and other organs. As the prevalence of diabetes is growing, the demand for anti-hypertensive drugs is expected to increase. According to the IDF Diabetes Atlas 10th edition 2021, an estimated 537 million adults between the ages of 20-79 years are living with diabetes, and it is expected to reach 643 million by 2030.

Government funding for R&D activities and distribution is playing a role in boosting the market growth by making anti-hypertensive drugs more affordable, improving access, and increasing competition. For instance, in August 2023 , Eazymed Technologies Pvt Ltd. raised USD 500,000 from the Tamil Nadu Emerging Sector Seed Fund in India. The company will utilize the fund on new ventures in the supply chain, such as working directly with pharmaceutical companies to expand their presence in tier 2-3 cities. Such initiatives are boosting the anti-hypertensive drugs market growth.

Moreover, rising approvals of new anti-hypertensive drugs encourage pharmaceutical companies to invest in research & development of novel and effective treatment options, which is expected to offer lucrative opportunities for the key players. For instance, in May 2022, the FDA approved Tyvaso DPI (treprostinil) inhalation powder. Tyvaso DPI is a dry powder inhaler that delivers treprostinil, a vasodilator, directly to the lungs. Treprostinil works by dilating the pulmonary arteries, which reduces blood pressure in the lungs and improves exercise capacity.

Anti-hypertensive Drugs Market Report Highlights:

• Based on drug class, the calcium channel blockers segment dominated the market in 2023 owing to their intrinsic property in combination with other anti-hypertensive drugs
• Based on type, the primary hypertension segment held the largest segment share of the market in 2023, owing to the increasing geriatric population and changing lifestyle factors, such as diet, physical inactivity, obesity, smoking, and excessive alcohol consumption
• Based on route of administration, the oral segment held the largest share due to its convenience, effectiveness, and patient-centered approach
• Based on distribution channel, the hospital pharmacies dominated the market, owing to the rise in hospitals worldwide, offering a wide range of healthcare services
• North America has established a strong regional position with a 37.55% market share owing to the increasing investment by private players, favorable government and insurance policies, technological advancements, and key regional operating players

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation
  • 1.1.1. Market Definitions
• 1.2. Objectives
  • 1.2.1. Objective - 1
  • 1.2.2. Objective - 2
  • 1.2.3. Objective - 3
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. Gvr's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
• 1.8. List Of Secondary Sources
• 1.9. List Of Abbreviations
• 1.10. List Of Primary Sources

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Type and Drug Class Snapshot
• 2.3. Route of Administration and Distribution Channel Snapshot
• 2.4. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Segmentation and Scope
• 3.2. Market Lineage Outlook
  • 3.2.1. Parent Market Outlook
  • 3.2.2. Related/Ancillary Market Outlook
• 3.3. Market Dynamics
• 3.4. Market Drivers
  • 3.4.1. Increasing the Prevalence of Hypertension and High Blood Pressure
  • 3.4.2. Growing Geriatric Population
  • 3.4.3. Development of New and More Effective Anti-Hypertensive Drugs
• 3.5. Market Restraint Analysis
  • 3.5.1. Side Effects of Anti-Hypertensive Drugs
  • 3.5.2. Regulatory Challenges
• 3.6. Business Environment Analysis
  • 3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
  • 3.6.2. Porter's Five Forces Analysis

Chapter 4. Drug Class Business Analysis

• 4.1. Anti-hypertensive Drugs Market: Drug Class Movement Analysis
• 4.2. Diuretics
  • 4.2.1. Diuretics Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.3. ACE Inhibitors
  • 4.3.1. ACE Inhibitors Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.4. Calcium Channel Blockers
  • 4.4.1. Calcium Channel Blockers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Beta-adrenergic Blockers
  • 4.5.1. Beta-adrenergic Blockers Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Vasodilators
  • 4.6.1. Vasodilators Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.7. Others
  • 4.7.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Type Business Analysis

• 5.1. Anti-hypertensive Drugs Market: Type Movement Analysis
• 5.2. Primary Hypertension
  • 5.2.1. Primary Hypertension Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.3. Secondary Hypertension
  • 5.3.1. Secondary Hypertension Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Route of Administration Business Analysis

• 6.1. Anti-hypertensive Drugs Market: Route of Administration Movement Analysis
• 6.2. Oral
  • 6.2.1. Oral Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.3. Injectables
  • 6.3.1. Injectables Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.4. Others
  • 6.4.1. Others Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Distribution Channel Business Analysis

• 7.1. Anti-hypertensive Drugs Market: Route of Administration Movement Analysis
• 7.2. Retail Pharmacy
  • 7.2.1. Retail Pharmacy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.3. Hospital Pharmacy
  • 7.3.1. Hospital Pharmacy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.4. Online Pharmacy
  • 7.4.1. Online Pharmacy Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Regional Business Analysis

• 8.1. Anti-hypertensive Drugs Market Share By Region, 2023 & 2030
• 8.2. North America
  • 8.2.1. North America Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.2.2. U.S.
    • 8.2.2.1. Key Country Dynamics
    • 8.2.2.2. Target Disease Prevalence
    • 8.2.2.3. Competitive Scenario
    • 8.2.2.4. Regulatory Framework
    • 8.2.2.5. Reimbursement Scenario
    • 8.2.2.6. U.S. Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.2.3. Canada
    • 8.2.3.1. Key Country Dynamics
    • 8.2.3.2. Target Disease Prevalence
    • 8.2.3.3. Competitive Scenario
    • 8.2.3.4. Regulatory Framework
    • 8.2.3.5. Reimbursement Scenario
    • 8.2.3.6. Canada Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.3. Europe
  • 8.3.1. Europe Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.2. Germany
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Target Disease Prevalence
    • 8.3.2.3. Competitive Scenario
    • 8.3.2.4. Regulatory Framework
    • 8.3.2.5. Reimbursement Scenario
    • 8.3.2.6. Germany Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.3. UK
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Target Disease Prevalence
    • 8.3.3.3. Competitive Scenario
    • 8.3.3.4. Regulatory Framework
    • 8.3.3.5. Reimbursement Scenario
    • 8.3.3.6. UK Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.4. France
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Target Disease Prevalence
    • 8.3.4.3. Competitive Scenario
    • 8.3.4.4. Regulatory Framework
    • 8.3.4.5. Reimbursement Scenario
    • 8.3.4.6. France Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.5. Italy
    • 8.3.5.1. Key Country Dynamics
    • 8.3.5.2. Target Disease Prevalence
    • 8.3.5.3. Competitive Scenario
    • 8.3.5.4. Regulatory Framework
    • 8.3.5.5. Reimbursement Scenario
    • 8.3.5.6. Italy Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.6. Spain
    • 8.3.6.1. Key Country Dynamics
    • 8.3.6.2. Target Disease Prevalence
    • 8.3.6.3. Competitive Scenario
    • 8.3.6.4. Regulatory Framework
    • 8.3.6.5. Reimbursement Scenario
    • 8.3.6.6. Spain Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.7. Denmark
    • 8.3.7.1. Key Country Dynamics
    • 8.3.7.2. Target Disease Prevalence
    • 8.3.7.3. Competitive Scenario
    • 8.3.7.4. Regulatory Framework
    • 8.3.7.5. Reimbursement Scenario
    • 8.3.7.6. Denmark Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.8. Sweden
    • 8.3.8.1. Key Country Dynamics
    • 8.3.8.2. Target Disease Prevalence
    • 8.3.8.3. Competitive Scenario
    • 8.3.8.4. Regulatory Framework
    • 8.3.8.5. Reimbursement Scenario
    • 8.3.8.6. Sweden Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.9. Norway
    • 8.3.9.1. Key Country Dynamics
    • 8.3.9.2. Target Disease Prevalence
    • 8.3.9.3. Competitive Scenario
    • 8.3.9.4. Regulatory Framework
    • 8.3.9.5. Reimbursement Scenario
    • 8.3.9.6. Norway Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.4. Asia Pacific
  • 8.4.1. Asia Pacific Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.2. Japan
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Target Disease Prevalence
    • 8.4.2.3. Competitive Scenario
    • 8.4.2.4. Regulatory Framework
    • 8.4.2.5. Reimbursement Scenario
    • 8.4.2.6. Japan Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.3. China
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Target Disease Prevalence
    • 8.4.3.3. Competitive Scenario
    • 8.4.3.4. Regulatory Framework
    • 8.4.3.5. Reimbursement Scenario
    • 8.4.3.6. China Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.4. India
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Target Disease Prevalence
    • 8.4.4.3. Competitive Scenario
    • 8.4.4.4. Regulatory Framework
    • 8.4.4.5. Reimbursement Scenario
    • 8.4.4.6. India Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.5. South Korea
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Target Disease Prevalence
    • 8.4.5.3. Competitive Scenario
    • 8.4.5.4. Regulatory Framework
    • 8.4.5.5. Reimbursement Scenario
    • 8.4.5.6. South Korea Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.6. Australia
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Target Disease Prevalence
    • 8.4.6.3. Competitive Scenario
    • 8.4.6.4. Regulatory Framework
    • 8.4.6.5. Reimbursement Scenario
    • 8.4.6.6. Australia Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.7. Thailand
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Target Disease Prevalence
    • 8.4.7.3. Competitive Scenario
    • 8.4.7.4. Regulatory Framework
    • 8.4.7.5. Reimbursement Scenario
    • 8.4.7.6. Thailand Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.5. Latin America
  • 8.5.1. Latin America Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.2. Brazil
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Target Disease Prevalence
    • 8.5.2.3. Competitive Scenario
    • 8.5.2.4. Regulatory Framework
    • 8.5.2.5. Reimbursement Scenario
    • 8.5.2.6. Brazil Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.3. Mexico
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Target Disease Prevalence
    • 8.5.3.3. Competitive Scenario
    • 8.5.3.4. Regulatory Framework
    • 8.5.3.5. Reimbursement Scenario
    • 8.5.3.6. Mexico Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.4. Argentina
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Target Disease Prevalence
    • 8.5.4.3. Competitive Scenario
    • 8.5.4.4. Regulatory Framework
    • 8.5.4.5. Reimbursement Scenario
    • 8.5.4.6. Argentina Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.6. MEA
  • 8.6.1. MEA Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.2. South Africa
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Target Disease Prevalence
    • 8.6.2.3. Competitive Scenario
    • 8.6.2.4. Regulatory Framework
    • 8.6.2.5. Reimbursement Scenario
    • 8.6.2.6. South Africa Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.3. Saudi Arabia
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Target Disease Prevalence
    • 8.6.3.3. Competitive Scenario
    • 8.6.3.4. Regulatory Framework
    • 8.6.3.5. Reimbursement Scenario
    • 8.6.3.6. Saudi Arabia Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.4. UAE
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Target Disease Prevalence
    • 8.6.4.3. Competitive Scenario
    • 8.6.4.4. Regulatory Framework
    • 8.6.4.5. Reimbursement Scenario
    • 8.6.4.6. UAE Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.5. Kuwait
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Target Disease Prevalence
    • 8.6.5.3. Competitive Scenario
    • 8.6.5.4. Regulatory Framework
    • 8.6.5.5. Reimbursement Scenario
    • 8.6.5.6. Kuwait Anti-hypertensive Drugs Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Participant's overview
• 9.2. Financial performance
• 9.3. Participant categorization
  • 9.3.1. Market Leaders
  • 9.3.2. Anti-hypertensive Drugs Market Share Analysis, 2023
  • 9.3.3. Company Profiles
    • 9.3.3.1. Sanofi
    • 9.3.3.1.1. Company Overview
    • 9.3.3.1.2. Financial Performance
    • 9.3.3.1.3. Product Benchmarking
    • 9.3.3.1.4. Strategic Initiatives
    • 9.3.3.2. Boehringer Ingelheim International GmbH
    • 9.3.3.2.1. Company Overview
    • 9.3.3.2.2. Financial Performance
    • 9.3.3.2.3. Product Benchmarking
    • 9.3.3.2.4. Strategic Initiatives
    • 9.3.3.3. Novartis AG
    • 9.3.3.3.1. Company Overview
    • 9.3.3.3.2. Financial Performance
    • 9.3.3.3.3. Product Benchmarking
    • 9.3.3.3.4. Strategic Initiatives
    • 9.3.3.4. Johnson & Johnson Services, Inc.
    • 9.3.3.4.1. Company Overview
    • 9.3.3.4.2. Financial Performance
    • 9.3.3.4.3. Product Benchmarking
    • 9.3.3.4.4. Strategic Initiatives
    • 9.3.3.5. DAIICHI SANKYO COMPANY, LIMITED.
    • 9.3.3.5.1. Company Overview
    • 9.3.3.5.2. Financial Performance
    • 9.3.3.5.3. Product Benchmarking
    • 9.3.3.5.4. Strategic Initiatives
    • 9.3.3.6. Merck & Co., Inc.
    • 9.3.3.6.1. Company Overview
    • 9.3.3.6.2. Financial Performance
    • 9.3.3.6.3. Product Benchmarking
    • 9.3.3.6.4. Strategic Initiatives
    • 9.3.3.7. AstraZeneca
    • 9.3.3.7.1. Company Overview
    • 9.3.3.7.2. Financial Performance
    • 9.3.3.7.3. Product Benchmarking
    • 9.3.3.7.4. Strategic Initiatives
    • 9.3.3.8. Pfizer Inc.
    • 9.3.3.8.1. Company Overview
    • 9.3.3.8.2. Financial Performance
    • 9.3.3.8.3. Product Benchmarking
    • 9.3.3.8.4. Strategic Initiatives
    • 9.3.3.9. Lupin
    • 9.3.3.9.1. Company Overview
    • 9.3.3.9.2. Financial Performance
    • 9.3.3.9.3. Product Benchmarking
    • 9.3.3.9.4. Strategic Initiatives
    • 9.3.3.10. Sun Pharmaceutical Industries Ltd.
    • 9.3.3.10.1. Company Overview
    • 9.3.3.10.2. Financial Performance
    • 9.3.3.10.3. Product Benchmarking
    • 9.3.3.10.4. Strategic Initiatives
  • 9.3.4. Strategy Mapping
    • 9.3.4.1. Expansion
    • 9.3.4.2. Acquisition
    • 9.3.4.3. Collaborations
    • 9.3.4.4. Disease Type/Drug Class Launch
    • 9.3.4.5. Partnerships
    • 9.3.4.6. Others